Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.29 - $66.54
Previous CloseN/A
Volume110.15K
Average Volume (3M)624.05K
Market Cap
$1.24B
Enterprise Value$1.74B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Feb 25, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding40,304,466
10 Day Avg. Volume414,512
30 Day Avg. Volume624,055
Standard Deviation0.16
R-Squared0.14
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.68
Price to Cash Flow (P/CF)477.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit32.38
Enterprise Value/Ebitda-57.05
Forecast
1Y Price Target
$47.71Price Target Upside55.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRxsight, Inc.'s preliminary Q4 revenue of $40.2MM was largely in line with consensus and beat the analyst's estimate, indicating strong performance.
Market PositionThe company's premium IOL market share is estimated to be over 10% in North America, suggesting a strong competitive position.
Revenue GuidanceRXST provided 2025 revenue guidance that exceeded consensus expectations, indicating confidence in future growth.
Bears Say
Competitive PressureA large part of the issue is the de-rating of some other fast growing MedTech SMIDs, but it's also fair to say there's a bit more competition than expected leading to slightly lower visibility.
Growth Deceleration4Q24 LAL units resulted in estimated year-over-year utilization growth of just +9%, a meaningful deceleration from the prior five quarters’ growth ranging from +17%-22%.
Revenue Growth Concerns4Q24 results were soft on both sides of RXST’s business, as total revenue of $40.2MM essentially matched consensus but showed the lowest level of growth since early-2021.
---
Ownership Overview
4.88% Insiders
20.10% Mutual Funds
33.11% Other Institutional Investors
27.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $26.29 and its highest was $66.54 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $1.24B.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Feb 25, 2025 which is in 4 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Nov 07, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.086.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.17.
How many shares outstanding does RxSight have?
RxSight has 40,304,466 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -5.585%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
---
RxSight Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.71 (55.26% Upside)
$47.71 (55.26% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $100.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.07%
12-Months-Change
Fundamentals
Return on Equity
-13.99%
Trailing 12-Months
Asset Growth
70.73%
Trailing 12-Months
Company Description
RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
---
RXST Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive trajectory for RxSight with strong revenue and sales growth, particularly in LAL and LDD units. The company has improved gross margins and revised its revenue guidance upwards. However, these positive developments are tempered by a net loss for the quarter and increased operating expenses. Additionally, external factors like hurricanes have had some impact on operations.Read More>---
RXST Stock 12 Month Forecast
Average Price Target
$47.71
▲(55.26% Upside)
Technical Analysis
Align Tech
―
Cooper Co
―
Staar Surgical
―
Zimmer Biomet Holdings
―
National Vision Holdings
―
Best Analysts Covering RXST
1 Year
1 Year Success Rate
14/21 ratings generated profit
1 Year Average Return
+69.81%
reiterated a buy rating last month
Copying David Saxon's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +69.81% per trade.
---